Could carbon monoxide help Parkinson's? small trial begins
Symptom relief
Recruiting now
This phase 2a trial tests an oral liquid containing low-dose carbon monoxide (HBI-002) in 36 people with Parkinson's disease. Participants take it daily for 14 days to see if it is safe and tolerable. The study is randomized and placebo-controlled, meaning some get the drug and s…
Phase: PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC